Buggestephansen2876

Crohn's disease (CD), a type of inflammatory bowel disease (IBD), emerges with severe gastrointestinal (GI) tract inflammation, sometimes known as hostile abdomen. Conventional treatment of CD has several limitations such as insufficient response to treatment, and intolerable side effects of drugs. In addition, the high cost of biologic drugs prevents patients from continuing their treatment. Dapsone showed vigorous anti-inflammatory effects on the skin diseases, lung diseases and inflammatory diseases of the nervous system. Hence, we decided to investigate the effect of dapsone on animal model of CD.

In this study, colitis was induced by instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS) 100 mg/kg. Rats were treated with daily gavage of dapsone (10, 12.5 and 20 mg/kg). Seven days after induction of colitis, specimens were collected for pathological and molecular assessments.

Dapsone (12.5 and 20 mg/kg) preserved the histologic architecture of the colon and prevented crypts irregularity. Additionally, it decreased tissue edema and hindered inflammatory cells infiltration. Besides, all doses of dapsone decreased tissue concentration of tumor necrosis factor α (TNF-α) and interferon γ (INFγ). Western blot revealed that dapsone could attenuate inflammation via downregulation of toll-like receptor 4 (TLR4) and dephosphorylation of nuclear factor kB (NF-kB).

Based on these findings, dapsone attenuates inflammation and decreases TNF-α and INF-γ in animal model of CD. It acts through TLR4/NF-kB pathway to exert these effects.

Based on these findings, dapsone attenuates inflammation and decreases TNF-α and INF-γ in animal model of CD. It acts through TLR4/NF-kB pathway to exert these effects.

The ongoing Coronavirus Infectious Disease (COVID-19) pandemic is a global health crisis that has had a magnanimous worldwide impact on all aspects of people's lives. Several observational studies investigated the relationship between Proton Pump Inhibitors use and the risk of COVID-19 development and mortality.

The aim of this meta-analysis is to investigate the association between current PPIs use and the development of COVID-19 as well as its mortality.

Pubmed, Google Scholar, ScienceDirect and medRxiv were searched until November 21, 2020 using the following keywords proton pump inhibitors and COVID-19 as well as their related MESH terms. The studies considered in the meta-analysis were either cohort or case-control in design and adjusted for confounding factors. 6-OHDA in vivo The quality of the studies included in this meta-analysis was assessed using the Newcastle-Ottawa Scale. In addition, a random-effects model was used to calculate the pooled Odds Ratio (ORs) and the corresponding confidence interval (95% CI). Heterogeneity was evaluated using The Cochran's Q heterogeneity test and I

statistic.

Six observational studies with 195,230 participants were included. In this meta-analysis, current use of PPIs increased risk of COVID-19 development (OR = 1.19; 95% CI 0.62-2.28) and mortality (OR = 1.67; 95% CI 1.41-1.97).

Our meta-analysis indicates that current PPIs use significantly increased the risk of COVID-19 mortality, but it did not reach a significant threshold in regards to the risk of COVID-19 development.

Our meta-analysis indicates that current PPIs use significantly increased the risk of COVID-19 mortality, but it did not reach a significant threshold in regards to the risk of COVID-19 development.

To assess renal and hepatic functions along with the redox state in preeclampsia (PE) and gestational diabetes mellitus (GDM) pregnancies.

The study was conducted on 33 PE (mean age = 30 ± 5 years), 33 GDM (mean age = 30 ± 6 years) and age, gravida, parity, and ethnicity matched 25 normal pregnancies (NP). Biomarkers of redox status, renal and hepatic functions; aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), bilirubin, urea, blood urea nitrogen (BUN), creatinine, uric acid, lipid peroxidation (MDA), total thiols (TSH), radical scavenging activities and ferric reducing antioxidant potentials of serum were measured.

Higher urea, BUN, uric acid, creatinine and overexpressed AST, ALT, ALP was observed in PE (p <0.03-p<0.001), whereas in GDM elevation in creatinine and ALT activity were only statistically significant (p <0.01) in comparison to NP. Diminished antioxidant/radical scavenging potentials, TSH content and increased MDA were noted in both the diseased pregnancies when compared with NP with statistically significant variables ranged from p <0.04-p <0.0001.

Our data suggest that PE has detrimental effects on renal and hepatic functions while GDM are prone to malfunctioned liver and kidney performances. Impaired redox state may be one of the reasons of altered physiological process in PE and GDM pregnancies. Results may be used to monitor the efficiency and efficacy of antioxidant supplementation, recently suggested for PE and GDM patients.

Our data suggest that PE has detrimental effects on renal and hepatic functions while GDM are prone to malfunctioned liver and kidney performances. Impaired redox state may be one of the reasons of altered physiological process in PE and GDM pregnancies. Results may be used to monitor the efficiency and efficacy of antioxidant supplementation, recently suggested for PE and GDM patients.

In patients with end-stage renal failure, hypervolemia frequently causes increased cardiac output, especially in patients who are under-dialyzed and those with cardiac decompensation.

This study aimed to examined the effect of kidney transplantation on valvular heart diseases.

This retrospective data analysis included adult patients (n=180) who underwent kidney transplantation between February 2015 and June 2018 at the Division of Organ Transplantation, University of Debrecen, Hungary. This study examined the echocardiographic parameters and laboratory results preoperatively and postoperatively (at 6 and 12 months). Statistical analyses were performed using the χ

/Fisher exact tests and Kruskal-Wallis analysis of variance test. P < .05 was considered significant.

No mitral regurgitation (MR) was observed preoperatively in 27% of the patients, while 62% had grade 1 MR, and 11% had grade 2 MR. Grade 2 MR was reduced from 11% to 2% twelve months after kidney transplantation (P=.03). Valvular calcification was detected preoperatively in 21.